JP2021512965A5 - - Google Patents
Info
- Publication number
- JP2021512965A5 JP2021512965A5 JP2020564822A JP2020564822A JP2021512965A5 JP 2021512965 A5 JP2021512965 A5 JP 2021512965A5 JP 2020564822 A JP2020564822 A JP 2020564822A JP 2020564822 A JP2020564822 A JP 2020564822A JP 2021512965 A5 JP2021512965 A5 JP 2021512965A5
- Authority
- JP
- Japan
- Prior art keywords
- neo
- cancer
- antibody
- treg cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024155435A JP2024177188A (ja) | 2018-02-13 | 2024-09-10 | Ｔｒｅｇ細胞を標的とするための方法及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630084P | 2018-02-13 | 2018-02-13 | |
| US62/630,084 | 2018-02-13 | ||
| PCT/US2019/017870 WO2019160970A1 (en) | 2018-02-13 | 2019-02-13 | Methods and compositions for targeting treg cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024155435A Division JP2024177188A (ja) | 2018-02-13 | 2024-09-10 | Ｔｒｅｇ細胞を標的とするための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512965A JP2021512965A (ja) | 2021-05-20 |
| JP2021512965A5 true JP2021512965A5 (https=) | 2022-02-17 |
| JP7555270B2 JP7555270B2 (ja) | 2024-09-24 |
Family
ID=67619085
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564822A Active JP7555270B2 (ja) | 2018-02-13 | 2019-02-13 | Ｔｒｅｇ細胞を標的とするための方法及び組成物 |
| JP2024155435A Pending JP2024177188A (ja) | 2018-02-13 | 2024-09-10 | Ｔｒｅｇ細胞を標的とするための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024155435A Pending JP2024177188A (ja) | 2018-02-13 | 2024-09-10 | Ｔｒｅｇ細胞を標的とするための方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12037410B2 (https=) |
| EP (1) | EP3752533A4 (https=) |
| JP (2) | JP7555270B2 (https=) |
| CN (1) | CN112041343B (https=) |
| AU (2) | AU2019221544B2 (https=) |
| BR (1) | BR112020016374A2 (https=) |
| CA (1) | CA3091181A1 (https=) |
| MX (2) | MX2020008415A (https=) |
| WO (1) | WO2019160970A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022246066A2 (en) * | 2021-05-19 | 2022-11-24 | Precision Biologics, Inc. | Methods and compositions for treating hematological malignancies |
| CN114010803B (zh) * | 2021-11-30 | 2023-04-07 | 广东省人民医院 | 一种检测活体肿瘤微环境中Treg细胞的多功能靶向分子探针及其应用 |
| AU2023272108A1 (en) * | 2022-05-19 | 2024-11-07 | Precision Biologics, Inc. | Methods for ablating myeloid derived suppressor cells using neo-201 antibody |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2010A (en) | 1841-03-18 | Machine foe | ||
| US4810781A (en) | 1987-01-15 | 1989-03-07 | The George Washington University | Methods of preparing epitopes of tumor associated antigens |
| USRE39760E1 (en) | 1988-03-31 | 2007-08-07 | International Bio-Immune Systems Inc. | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor |
| US5688657A (en) | 1988-03-31 | 1997-11-18 | International Bio-Immune Systems, Inc. | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor |
| EP1320551A4 (en) | 2000-09-01 | 2006-12-20 | Internat Bioimmune Systems Inc | IDENTIFICATION AND DEVELOPMENT OF SPECIFIC MONOCLONAL ANTIBODIES AGAINST SQUAFTEPITHELIC CARCINOMA |
| JP2004537976A (ja) | 2001-03-15 | 2004-12-24 | インターナショナル バイオイムン システムズ，インコーポレーテッド | 膵癌のモノクローナル抗体治療 |
| CA2604238C (en) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| WO2008103905A2 (en) * | 2007-02-23 | 2008-08-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies that specifically bind irta and methods of use |
| CA2700197C (en) | 2007-11-08 | 2020-09-08 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| US8277804B2 (en) * | 2008-05-21 | 2012-10-02 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US20120064100A1 (en) | 2009-03-18 | 2012-03-15 | Simon Barry | Biomarkers and uses thereof |
| WO2011139738A2 (en) * | 2010-04-28 | 2011-11-10 | Tenx Biopharma, Inc. | Therapies using zanolimumab to enhance the immune response |
| US20130189268A1 (en) | 2010-06-22 | 2013-07-25 | Precision Biologics, Inc. | Colon and pancreas cancer specific antigens and antibodies |
| ES2719624T3 (es) | 2010-09-23 | 2019-07-11 | Prec Biologics Inc | Peptidomiméticos de cáncer de colon y de páncreas |
| WO2012075111A1 (en) * | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| JP2013059295A (ja) * | 2011-09-14 | 2013-04-04 | Nagoya City Univ | ｓｉＲＮＡ、抗原提示細胞、制御性Ｔ細胞及び治療薬 |
| CN105188749B (zh) * | 2012-12-21 | 2017-12-19 | 西雅图基因公司 | 抗ntb‑a抗体及相关组合物和方法 |
| CA2896723C (en) | 2012-12-28 | 2024-02-13 | Precision Biologics, Inc. | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer |
| WO2014163684A1 (en) * | 2013-04-03 | 2014-10-09 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| AU2014319921A1 (en) * | 2013-09-11 | 2016-03-17 | Compugen Ltd. | Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis |
| PE20171790A1 (es) * | 2015-03-23 | 2017-12-28 | Bayer Pharma AG | Anticuerpos anti-ceacam6 y sus usos |
| US11279768B1 (en) * | 2015-04-03 | 2022-03-22 | Precision Biologics, Inc. | Anti-cancer antibodies, combination therapies, and uses thereof |
| EP3295171A1 (en) * | 2015-05-12 | 2018-03-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof |
| KR20190017735A (ko) * | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| WO2018218230A1 (en) * | 2017-05-26 | 2018-11-29 | Etubics Corporation | Combination immunotherapies comprising il-15 superagonists |
| WO2019090134A1 (en) * | 2017-11-03 | 2019-05-09 | Precision Biologics, Inc. | Monoclonal antibody neo-201 for the treatment of human carcinomas |
| WO2020018425A1 (en) * | 2018-07-16 | 2020-01-23 | Nantcell, Inc. | Antibody-dependent cell-mediated toxicity mediated by alt-803 and neo-201 |
-
2019
- 2019-02-13 AU AU2019221544A patent/AU2019221544B2/en active Active
- 2019-02-13 JP JP2020564822A patent/JP7555270B2/ja active Active
- 2019-02-13 BR BR112020016374-0A patent/BR112020016374A2/pt unknown
- 2019-02-13 CN CN201980013096.6A patent/CN112041343B/zh active Active
- 2019-02-13 US US16/969,268 patent/US12037410B2/en active Active
- 2019-02-13 WO PCT/US2019/017870 patent/WO2019160970A1/en not_active Ceased
- 2019-02-13 MX MX2020008415A patent/MX2020008415A/es unknown
- 2019-02-13 EP EP19754490.1A patent/EP3752533A4/en active Pending
- 2019-02-13 CA CA3091181A patent/CA3091181A1/en active Pending
-
2020
- 2020-08-11 MX MX2025010847A patent/MX2025010847A/es unknown
-
2024
- 2024-06-07 US US18/737,186 patent/US20240400714A1/en active Pending
- 2024-09-10 JP JP2024155435A patent/JP2024177188A/ja active Pending
-
2025
- 2025-10-07 AU AU2025248631A patent/AU2025248631A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI878150B (zh) | 嵌合抗原及t細胞受體以及使用方法 | |
| Hegde et al. | Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape | |
| CN107827990B (zh) | 一种多肽、编码其的核酸、其修饰的t淋巴细胞及其应用 | |
| AU2018250336B2 (en) | Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods | |
| JP7280827B2 (ja) | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 | |
| AU2025205147A1 (en) | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies | |
| KR102823603B1 (ko) | 면역요법을 위한 t 세포 수용체 | |
| WO2019094559A2 (en) | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides | |
| CN111201038A (zh) | Psgl-1拮抗剂及其用途 | |
| KR20210061350A (ko) | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드 | |
| KR20200015717A (ko) | 암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용 | |
| US20240317890A1 (en) | Her2 single domain antibodies variants and cars thereof | |
| JP2021512965A5 (https=) | ||
| KR20230088306A (ko) | 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법 | |
| CN114599677A (zh) | 用于治疗b细胞恶性肿瘤的靶向细胞表面标记物cd72的免疫疗法 | |
| JP2025072546A (ja) | 血液疾患を治療するためのキット | |
| TW202300014A (zh) | 腫瘤儲存及細胞培養組成物 | |
| ES2744936T3 (es) | Método para evaluar el efecto terapéutico de un agente antineoplásico que tiene un anticuerpo anti-CD4 como principio activo | |
| Alahmari | Discovery of anti-LAG-3 peptides and construction of a hybrid single-domain antibody phage display library for cancer immunotherapy | |
| US20250041413A1 (en) | Multi-Cytokine Surface Loaded Particles and Uses in Stimulating Immune Cells for Therapeutic Applications | |
| JP2021028293A (ja) | 免疫抑制性ミエロイド細胞マーカー | |
| WO2025221781A2 (en) | Chimeric antigen receptors targeting fgfr4 and/or cd276 and use thereof for the treatment of cancer | |
| US20250304718A1 (en) | Her2 single domain antibody and uses thereof | |
| WO2023235479A1 (en) | Compositions and methods for treating cancer | |
| WO2024233970A2 (en) | Enrichment and expansion of chimeric antigen receptor t cells using antigen-presenting biomaterials |